Eagle Pharmaceuticals (EGRX) Misses Q1 EPS by 9c

Eagle Pharmaceuticals (NASDAQ: EGRX) reported Q1 EPS of $1.38, $0.09 worse than the analyst estimate of $1.47. Revenue for the quarter came in at $36.3 million versus the consensus estimate of $3.41 million.

For earnings history and earnings-related data on Eagle Pharmaceuticals (EGRX) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Wintermar acquires full control of Fast Offshore Supply, adding 5 new CTVs
• FirstCash to acquire UK pawn operator Ramsdens for £206 million